GlaxoSmithKline plc (LSE: GSK NYSE: GSK), often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is the world's third largest pharmaceutical company measured by revenues (after Johnson & Johnson and Pfizer). It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions. It also has a large consumer healthcare division which produces and markets oral healthcare products, nutritional drinks and over-the-counter medicines, including Sensodyne, Horlicks and Gaviscon.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2012 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationfederal data covers roughly through Q2 2014
state-level data is not available in bulk for 2014. for current state data, browse http://followthemoney.org/
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of GlaxoSmithKline
Names of Lobbyists
Firm Hired Amount GlaxoSmithKline $10,365,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Fed Budget & Appropriations,
- Copyright, Patent & Trademark,
- Foreign Relations,
- Small Business,
Most Frequently Disclosed Bills
Bill No. Title H.R.452 Medicare Decisions Accountability Act of 2011 H.R.1249 America Invents Act S.1699 Prescription Drug Cost Reduction Act H.R.3590 Service Members Home Ownership Tax Act of 2009 S.668 Health Care Bureaucrats Elimination Act H.R.5 Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011 H.R.942 American Research and Competitiveness Act of 2011 H.R.1930 Access to Appropriate Immunizations for Veterans Act of 2011 H.R.2190 Medicare Drug Savings Act of 2011 H.R.5651 Food and Drug Administration Reform Act of 2012
RegulationsMentioned in 142 dockets; Submitted to 23 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "GlaxoSmithKline" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for GlaxoSmithKline
- Toggle 1 FDA Classification of Products as Drugs and Devices & Additional Product Classification Issues; Draft Guidance for Industry and FDA Staff 2011
- Toggle 1 FDA Amendments to Sterility Test Requirements for Biological Products 2011
- Toggle 1 FDA Draft Documents to Support Submission of an Electronic Common Technical Document; Availability 2011
- Toggle 1 DEA Disposal of Controlled Substances 2012
- Toggle 1 FDA International Conference on Harmonisation; Draft Guidance on Q11 Development and Manufacture of Drug Substances; Availability 2011
- Toggle 1 PTO Changes to Implement the Supplemental Examination Provisions of the Leahy-Smith America Invents Act and to Revise Reexamination Fees 2011
- Toggle 1 DEA Schedules of Controlled Substances: Placement of Ezogabine Into Schedule V 2011
- Toggle 1 FDA Draft Guidance for IRBs, Clinical Investigators, and Sponsors: Considerations When Transferring Clinical Investigation Oversight to Another IRB; Availability 2011
- Toggle 1 FDA Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies; Availability 2011
- Toggle 1 FDA Orphan Drug Regulations 2011
Mentions in Document Text
View all mentions data for GlaxoSmithKline
- Toggle 7 FDA Advisory Committee, Workshops, and Conferences Notices Various Meeting Notices (eg., Task Force Meeting, etc.) 2012
- Toggle 6 FDA Advisory Committee, Workshops, and Conferences Notices Various Meeting Notices (eg., Task Force Meeting, etc.) 2011
- Toggle 5 FDA Advisory Opinion regarding certain drug delivery device patents submitted for listing in the Orange Book under Section 505 of the Federal Food, Drug, and Cosmetic Act 2011
- Toggle 4 CMS Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule, DME Face-to-Face Encounters, Elimination of the Requirement for Termination of Non-Random Prepayment Complex Medical Review and Other Revisions to Part B for CY 2013 (CMS-1590-P) 2012
- Toggle 4 FDA To Declare That the Product Ondansetron Effervescent Tablets 8 mg is Suitable for Submission as an Abbreviated New Drug Application (ANDA) - CLOSED 2011
- Toggle 4 CMS Hospital Outpatient Prospective Payment; Ambulatory Surgical Center Payment; Hospital Value-Based Purchasing Program; Physician Self-Referral; and Provider Agreement Regulations on Patient Notification Requirements 2011
- Toggle 4 CMS Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2012 2011
- Toggle 3 USTR 2013 Special 301 Review 2012
- Toggle 3 CMS Medicaid Program; Covered Outpatient Drugs (CMS-2345-P) 2012
- Toggle 3 FDA Draft Guidance for Industry on Use of Histology in Biomarker Qualification Studies; Availability 2011
Federal Spending15 contracts
Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.
Only grants, contracts and loans with amounts over $1 million are shown.
Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.
Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.
|Glaxosmithkline Llc||2012||Centers For Disease Control||VACCCINE FOR CHILDREN 2012||$148,967,648|
|Glaxosmithkline Llc||2012||Centers For Disease Control||VACCCINE FOR CHILDREN 2012||$95,970,006|
|Glaxosmithkline Llc||2012||Centers For Disease Control||VACCCINE FOR CHILDREN 2012||$59,648,298|
|Glaxosmithkline Llc||2012||Centers For Disease Control||VACCCINE FOR CHILDREN 2012||$40,922,066|
|Glaxosmithkline Llc||2011||Office Of Assistant Secretary For Management And Budget||RESEARCH AND DEVELOPMENT FACILITIES||$38,506,842|
|Glaxosmithkline Llc||2012||Centers For Disease Control||PEDIATRIC FLU VACCINE||$13,673,350|
|Glaxosmithkline Llc||2012||Centers For Disease Control||2012 GSK ADULT VACCINES||$8,728,937|
|Glaxosmithkline Llc||2012||Centers For Disease Control||GSK 2011 VFA||$7,464,818|
|Glaxosmithkline Llc||2012||Centers For Disease Control||VACCCINE FOR CHILDREN 2012||$5,939,967|
|Glaxosmithkline Llc||2011||Centers For Disease Control||GSK 2011 VFA||$5,442,235|
Contractor Misconduct9 Instances
This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.
More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.
|Misconduct Type||Hired By||Incident||Year||Disposition||Penalty|
|Health||None||2011 Criminal and Civil Investigations Settlement||2011||Settlement||$3,000,000,000|
|Health||None||Puerto Rico Drug Manufacturing Facility Settlement: State AGs||2011||Settlement||$40,750,000|
|Antitrust||None||Defrauding Louisiana's Medicaid Program||2012||Settlement||$10,000,000|
|Intellectual Property||None||Nigeria Trademark Infringement||2011||Judgment Against Defendant||$7,873,706|
|Antitrust||None||South Korea Antitrust Fine||2011||Fine||$2,651,737|
|Health||None||Argentina Vaccine Trials Fine||2012||Fine||$93,000|
|Health||None||Current Good Manufacturing Practice Violations at Worthing, UK Facility||2011||Investigative Finding||$0|
|Health||None||Louisiana Attorney General Avandia Lawsuit||2011||Pending||$0|
|Health||None||South Carolina Attorney General Avandia Lawsuit||2011||Pending||$0|
Advisory Committees3 people on 3 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "GlaxoSmithKline" that sat on federal advisory committees.
- Toggle Department of Health and Human Services 2 people on 2 committees
- Toggle Environmental Protection Agency 1 person on 1 committee